Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
I would interpret it the same way. I notice the publication date is 2005. It is also primarily a German endeavor, and that country hasn't been as quick as others to wholeheartedly adhere to IDSA Guidelines.
I wonder if there were ever any follow-up studies.
Incidentally, you would think the NIH would be following this lead, or even something similar, considering its principal, if not sole, focus these days is diagnostics.
It's been researched a fair bit regarding other infections, and it sounds like variations elsewhere in the gene often have a very significant impact.
23andMe data for the rest of the gene looks very normal for 31 patients I have full data for, when compared to 31 controls. One possible exception is rs3804100 where we have 2 patients and 0 controls who are homozygous for the rare version. The usual homozygous prevalence is 1.2%, but we're at 6.5%. It could just be a fluke though, since it's pretty small sample size.